鲁拉西酮跨诊断改善抑郁症状:系统综述与随机对照试验meta分析
汇总分析显示鲁拉西酮在改善抑郁评分上优于安慰剂(SMD -0.26,95% CI -0.37, -0.15),且可接受性与安全性更好、耐受性相当。结论认为鲁拉西酮是跨诊断减少抑郁症状的潜在有效且安全策略,但需更长期稳健试验验证。
要点
- 鲁拉西酮跨精神分裂症、双相障碍和重性抑郁障碍等多种诊断改善抑郁评分优于安慰剂。
- 鲁拉西酮可接受性(RR 0.55)与安全性(RR 0.73)优于安慰剂,耐受性相当(RR 0.74)。
- 纳入研究存在高偏倚风险与高异质性,证据确定性受限。
核心结论
- 鲁拉西酮是跨多种精神科诊断减少抑郁症状的潜在有效且安全策略。
- 仍需采用精准精神病学方法的长期稳健试验支持其跨诊断靶向抑郁症状的更广泛使用。
研究设计与样本
- 纳入比较鲁拉西酮与安慰剂对抑郁症状影响的随机对照试验,抑郁症状用任何标准化量表测量。
- 采用Cochrane偏倚风险工具评估研究质量,GRADE工具评估证据确定性,随机效应meta分析估计SMD或RR及95% CI。
主要发现
- 汇总分析显示鲁拉西酮改善抑郁评分优于安慰剂(SMD -0.26,95% CI -0.37, -0.15),覆盖精神分裂症、双相障碍和重性抑郁障碍等多种诊断。
- 次要分析显示鲁拉西酮可接受性优于安慰剂(RR 0.55,95% CI 0.43, 0.71)。
- 鲁拉西酮安全性优于安慰剂(RR 0.73,95% CI 0.58, 0.91)。
- 鲁拉西酮与安慰剂耐受性相当(RR 0.74,95% CI 0.54, 1.02)。
关键数值与推荐
- 抑郁评分改善:SMD -0.26(95% CI -0.37, -0.15),鲁拉西酮优于安慰剂。
- 可接受性:RR 0.55(95% CI 0.43, 0.71),鲁拉西酮优于安慰剂。
- 安全性:RR 0.73(95% CI 0.58, 0.91),鲁拉西酮优于安慰剂。
- 耐受性:RR 0.74(95% CI 0.54, 1.02),鲁拉西酮与安慰剂相当。
临床怎么用
- 对于伴抑郁症状的精神分裂症、双相障碍和重性抑郁障碍患者,鲁拉西酮可作为跨诊断改善抑郁的潜在治疗选择。
- 临床决策时应结合可接受性、安全性和耐受性数据综合评估鲁拉西酮的获益与风险。
局限性
- 若干纳入研究存在高偏倚风险。
- 研究结果观察到高异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lurasidone is a second-generation antipsychotic with antidepressant properties, but its effect on depressive symptoms across diagnostic domains is not known. AIMS: This systematic review aims to synthesise the evidence for the transdiagnostic efficacy of lurasidone in reducing depressive symptoms. METHOD: Electronic databases were searched up to October 2024 to identify randomised controlled trials comparing the effects of lurasidone and placebo on depressive symptoms, as measured by any standardised scale, in populations with different psychiatric diagnoses. Acceptability, tolerability and safety were also measured. The Cochrane risk of bias tool was used to assess study quality, and the GRADE tool to evaluate certainty of evidence. A random-effects meta-analysis was performed to estimate standardised mean differences (SMDs, for continuous outcomes) or relative risks (for dichotomous outcomes) with 95% CI. RESULTS: Fourteen trials met inclusion criteria. Pooled analysis of 5239 participants found lurasidone to be more efficacious than placebo in improving depression scores (SMD -0.26, 95% CI -0.37, -0.15) across multiple diagnoses (including schizophrenia, bipolar disorder and major depressive disorder). Secondary analyses showed better acceptability (relative risk 0.55, 95% CI 0.43, 0.71) and safety (relative risk 0.73, 95% CI 0.58, 0.91) and comparable tolerability (relative risk 0.74, 95% CI 0.54, 1.02) between lurasidone and placebo. The main limitations were the high risk of bias of several included studies and the high heterogeneity observed in our findings. CONCLUSION: Lurasidone is a potentially efficacious and safe strategy for reducing depressive symptomatology across a range of psychiatric diagnoses. Further long-term, robust trials employing precision psychiatry methods are needed to support its broader use to target depressive symptoms transdiagnostically.
引用
- Ghenciulescu A, Pearse A, Minichino A, et al. Transdiagnostic efficacy of lurasidone on depressive symptoms: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2025. PMID: 40831006. doi:10.1192/bjp.2025.10343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。